Skip to main content
SpringerLink
Log in

64Cu-Radiopharmaceuticals

  • Chapter
  • First Online:
Radiopharmaceuticals

Abstract

Copper (Cu) is a transition metal with atomic number 29, involved in several physiological processes, being cofactor for numerous enzymes, such as the “Cu/Zn superoxide dismutase,” “cytochrome-C-oxidase,” “tyrosinase,” “ceruloplasmin,” and other proteins. Moreover, the Cu is essential for respiration, iron transport and metabolism, cell growth, and hemostasis [1, 2]. It may also play a role in cancer development and progression, acting as neo-angiogenetic promoter [3, 4].

Authors declare they have obtained permission for any previously published material used in their chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

18F-FDG:

18F-fluorodeoxyglucose

18F-MISO:

18F-Misonidazole

64Cu-ATSM:

Diacetyl-bis-N4-methylthiosemicarbazone

64Cu-DOTANOC:

64Cu-tetraazacyclododecane-octreotid

64Cu-DOTATATE:

64Cu-tetraazacyclododecane-octreotate

64Cu-PSMA:

64Cu-prostate-specific membrane antigen

68Ga-DOTATOC:

68Ga-tetraazacyclododecane-octreotide

BFC:

Bi-functional-chelator

CTR1:

Human copper transporter 1

Cu:

Copper

DNA:

Deoxyribonucleic acid

DOTA:

Tetraazacyclododecane-tetraacetic acid

GMP:

Good manufacture practice

LET:

Linear energy transfer

NET:

Neuroendocrine tumors

PET/CT:

Positron emission tomography/computed tomography

PSMA:

Prostate-specific membrane antigen

RRT:

Receptors radiation therapy

SPECT/CT:

Single photon emission computed tomography/computed tomography

SSTR:

Somatostatin receptor

References

  1. Niccoli Asabella A, Cascini GL, Altini C, et al. The copper radioisotopes: a systematic review with special interest to 64Cu. Biomed Res Int. 2014;2014:786463.

    PubMed  PubMed Central  Google Scholar 

  2. Puig S, Thiele DJ. Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol. 2002;6:171–80.

    Article  CAS  PubMed  Google Scholar 

  3. Reilly W, McAuslan BR. Matrix control of tumor angiogenesis. Adv Exp Med Biol. 1988;242:221–7.

    Article  CAS  PubMed  Google Scholar 

  4. Finney L, Vogt S, Fukai T, et al. Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol. 2009;36:88–94.

    Article  CAS  PubMed  Google Scholar 

  5. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957–80.

    Article  CAS  PubMed  Google Scholar 

  6. Szymański P, Frączek T, Markowicz M, et al. Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012;25:1089–112.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Evangelista L, Luigi M, Cascini GL. New issues for copper-64: from precursor to innovative PET tracers in clinical oncology. Curr Radiopharm. 2013;6:117–23.

    Article  CAS  PubMed  Google Scholar 

  8. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46:4s–12s.

    PubMed  Google Scholar 

  9. George AM, Sabovljev SA, Hart LE, et al. DNA quaternary structure in the radiation sensitivity of human lymphocytes—a proposed role of copper. Br J Cancer Suppl. 1987;8:141–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Frindel M, Camus N, Rauscher A, et al. Radiolabeling of HTE1PA: a new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice. Nucl Med Biol. 2014;41:e49–57.

    Article  CAS  PubMed  Google Scholar 

  11. Banerjee SR, Pullambhatla M, Foss CA, et al. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J Med Chem. 2014;27:6.

    Google Scholar 

  12. Cai Z, Anderson CJ. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J Labelled Comp Radiopharm. 2014;57:224–30.

    Article  CAS  PubMed  Google Scholar 

  13. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24:379–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–40.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou Y, Li J, Xu X, et al. 64Cu-based Radiopharmaceuticals in Molecular Imaging. Technol Cancer Res Treat. 2019;1:1533033819830758.

    Google Scholar 

  16. Eder M, Eisenhut M, Babich J, et al. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819–23.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cui C, Hanyu M, Hatori A, et al. Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. Am J Nucl Med Mol Imaging. 2017;7:40–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Berliner C, Tienken M, Frenzel T, et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using 68Ga-PSMA;T and comparison with published data of 68Ga PSMA HBED-CC. Eur J Nucl Med Mol Imaging. 2017;44:670–7.

    Article  CAS  PubMed  Google Scholar 

  19. Buemel C, Krebs M, Polat B, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med. 2016;41:515–21.

    Article  Google Scholar 

  20. Grubmüller B, Baum RP, Capasso E, et al. 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother Radiopharm. 2016;31:277–86.

    Article  PubMed  CAS  Google Scholar 

  21. Calabria F, Gallo G, Schillaci O, et al. Bio-distribution, imaging protocols and diagnostic accuracy of PET with tracers of lipogenesis in imaging prostate cancer: a comparison between 11C-choline, 18F-fluoroethylcholine and 18F-methylcholine. Curr Pharm Des. 2015;21:4738–47.

    Article  CAS  PubMed  Google Scholar 

  22. Cantiello F, Crocerossa F, Russo GI, et al. Comparison between 64Cu-PSMA-617 PET/CT and 18F-choline PET/CT imaging in early diagnosis of prostate cancer biochemical recurrence. Clin Genitourin Cancer. 2018;16:385–91.

    Article  PubMed  Google Scholar 

  23. Huang YT, Fong W, Thomas P. Rectal carcinoma on 68Ga-PSMA PET/CT. Clin Nucl Med. 2016;41:167–8.

    Article  CAS  Google Scholar 

  24. Krohn T, Verburg FA, Pufe T, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.

    Article  PubMed  Google Scholar 

  25. Calabria F, Gangemi V, Gullà D, et al. 64Cu-PSMA uptake in meningioma: a potential pitfall of a promising radiotracer. Rev Esp Med Nucl Imagen Mol. 2017;36:335–6.

    CAS  PubMed  Google Scholar 

  26. Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT. Clin Nucl Med. 2016;41:956–8.

    Article  PubMed  Google Scholar 

  27. Calabria F. Fifty shades of meningioma: challenges and perspectives of different PET molecular probes. Clin Transl Imaging. 2017;5:403–5.

    Article  Google Scholar 

  28. Calabria F, Pichler R, Leporace M et al. 68Ga/64Cu PSMA bio-distribution in prostate cancer patients: potential pitfalls for different tracers. Curr Radiopharm. 2019 [Epub ahead of print].

    Google Scholar 

  29. Fallanca F, Giovacchini G, Picchio M, et al. Incidental detection by [11C]choline PET/CT of meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging. 2009;53:417–21.

    CAS  PubMed  Google Scholar 

  30. Strele-Trieb P, Dunzinger A, Sonnberger M, et al. Uptake of 68Ga-prostate-specific membrane antigen PET in Adrenal Gland: a potential pitfall. Clin Nucl Med. 2017;43:50–1.

    Article  Google Scholar 

  31. Keidar Z, Gill R, Goshen E, et al. 68Ga-PSMA PET/CT in prostate cancer patients - patterns of disease, benign findings and pitfalls. Cancer Imaging. 2018;18:39.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Jochumsen MR, Bouchelouche K. Intense 68Ga-PSMA uptake in diverticulum of the sigmoid colon. Clin Nucl Med. 2018;43:110–1.

    Article  PubMed  Google Scholar 

  33. Calabria FF, Chiaravalloti A, Jaffrain-Rea ML, et al. 18F-DOPA PET/CT physiological distribution and pitfalls: experience in 215 patients. Clin Nucl Med. 2016;41:753–60.

    Article  PubMed  Google Scholar 

  34. Calabria F, Chiaravalloti A, Cicciò C, et al. PET/CT with 18F-choline: physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nucl Med Biol. 2017;51:40–54.

    Article  CAS  PubMed  Google Scholar 

  35. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.

    CAS  PubMed  Google Scholar 

  36. Padhani AR, Krohn KA, Lewis JS, et al. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861–72.

    Article  PubMed  Google Scholar 

  37. Yuan H, Schroeder T, Bowsher JE, et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–98.

    CAS  PubMed  Google Scholar 

  38. Liu J, Hajibeigi A, Ren G, et al. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. J Nucl Med. 2009;50:1332–9.

    Article  CAS  PubMed  Google Scholar 

  39. Yoshii Y, Furukawa T, Kiyono Y, et al. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38:151–7.

    Article  CAS  PubMed  Google Scholar 

  40. Yoshii Y, Yoneda M, Ikawa M, et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol. 2012;39:177–85.

    Article  CAS  PubMed  Google Scholar 

  41. Nehmeh SA, Lee NY, Schröder H, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. McCall KC, Humm JL, Bartlett R, et al. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol Biol Phys. 2012;84:e393–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Carlin S, Zhang H, Reese M, et al. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med. 2014;55:515–21.

    Article  CAS  PubMed  Google Scholar 

  44. Tateishi K, Tateishi U, Sato M, et al. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:98–9.

    Article  Google Scholar 

  45. Minagawa Y, Shizukuishi K, Koike I, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med. 2011;25:339–45.

    Article  PubMed  Google Scholar 

  46. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–50.

    Article  CAS  PubMed  Google Scholar 

  47. Lopci E, Grassi I, Rubello D, et al. Prognostic evaluation of disease outcome in solid tumors investigated with 64Cu-ATSM PET/CT. Clin Nucl Med. 2016;41:e87–92.

    Article  PubMed  Google Scholar 

  48. Barrio M, Czernin J, Fanti S, et al. The impact of SSTR-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. J Nucl Med. 2017;58:756–61.

    Article  PubMed  Google Scholar 

  49. Hanaoka H, Tominaga H, Yamada K, et al. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med. 2009;23:559–667.

    Article  CAS  PubMed  Google Scholar 

  50. Anderson CJ, Pajeau TS, Edwards WB, et al. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med. 1995;36:2315–25.

    CAS  PubMed  Google Scholar 

  51. Pfeifer A, Knigge U, Mortensen J, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207–15.

    Article  CAS  PubMed  Google Scholar 

  52. Pfeifer A, Knigge U, Binderup T, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56:847–54.

    Article  CAS  PubMed  Google Scholar 

  53. Johnbeck CB, Knigge U, Loft A, et al. Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58:451–7.

    Article  CAS  PubMed  Google Scholar 

  54. Bahri H, Laurence L, Edeline J, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786–90.

    Article  CAS  PubMed  Google Scholar 

  55. Bhatkar D, Utpat K, Basu S, et al. Dual tracer PET imaging (68Ga-DOTATATE and 18F-FDG) features in pulmonary carcinoid: correlation with tumor proliferation index. Indian J Nucl Med. 2017;32:39–41.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Pedersen SF, Sandholt BV, Keller SH, et al. 64Cu-DOTATATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomy. Arterioscler Thromb Vasc Biol. 2015;35:1696–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Theranostics, “Mariano Santo” Hospital, Cosenza, Italy

    Ferdinando Calabria, Antonio Bagnato & Mario Leporace

  2. Nuclear Medicine Unit, Department of Diagnostic Imaging, “Magna Graecia” University, Catanzaro, Italy

    Vincenzo Gangemi, Rosina Paonessa & Giuseppe Lucio Cascini

  3. Nuclear Medicine Unit, University Hospital “Tor Vergata”, Rome, Italy

    Nicoletta Urbano

Authors
  1. Ferdinando Calabria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Bagnato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincenzo Gangemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosina Paonessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mario Leporace
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicoletta Urbano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giuseppe Lucio Cascini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ferdinando Calabria .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine and Theranostics, Mariano Santo Hospital, Cosenza, Italy

    Ferdinando Calabria

  2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

    Orazio Schillaci

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Calabria, F. et al. (2020). 64Cu-Radiopharmaceuticals. In: Calabria, F., Schillaci, O. (eds) Radiopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-030-27779-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27779-6_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27778-9

  • Online ISBN: 978-3-030-27779-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation